
==== Front
Heliyon
Heliyon
Heliyon
2405-8440
Elsevier

S2405-8440(24)13129-5
10.1016/j.heliyon.2024.e37098
e37098
Review Article
Chloroquine: Rapidly withdrawing from first-line treatment of COVID-19
Jia Yunlong 1
Tian Wenjie 1
Li Yuyao
Teng Yuyan
Liu Xiaolin
Li Zhengyu
Zhao Mingsheng mszhao1990@mail.jnmc.edu.cn
⁎
Institute of Immunology and Molecular Medicine, Jining Medical University, Jining, China
⁎ Corresponding author. mszhao1990@mail.jnmc.edu.cn
1 These authors contributed equally to this work.

28 8 2024
15 9 2024
28 8 2024
10 17 e3709816 8 2023
23 8 2024
27 8 2024
© 2024 The Authors
2024
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
The COVID-19 outbreak has garnered significant global attention due to its impact on human health. Despite its relatively low fatality rate, the virus affects multiple organ systems, resulting in various symptoms such as palpitations, headaches, muscle pain, and hearing loss among COVID-19 patients and those recovering from the disease. These symptoms impose a substantial physical, psychological, and social burden on affected individuals. On February 15, 2020, the Chinese government advised incorporating antimalarial drugs into the guidelines issued by the National Health Commission of China for preventing, diagnosing, and treating COVID-19 pneumonia. We examine the adverse effects of Chloroquine (CQ) in treating COVID-19 complications to understand why it is no longer the primary treatment for the disease.

Keywords

CQ
COVID-19
ACE2
Complications
Disorders
Toxity
==== Body
pmc1 Introduction

COVID-19, a highly contagious respiratory illness, stems from Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), a new virus identified in December 2019 [1]. By early 2020, the World Health Organization recognized the COVID-19 outbreak as a global health emergency, officially declaring it a pandemic on March 11, 2020 [2]. While most individuals infected with SARS-CoV-2 experience mild or no symptoms, some suffer severe illness and may succumb to COVID-19-related complications [[3], [4], [5]].

COVID-19 presents with systemic inflammation, cytokine storm [6], multi-organ dysfunctions, and immune response dysregulation. On one hand, SARS-CoV-2 infection can trigger uncontrolled inflammatory responses by activating both innate and adaptive immune responses [7]. This activation prompts activated macrophages to produce various pro-inflammatory cytokines like Tumor Necrosis Factor (TNF)-α, Interleukin (IL)-1, IL-6, and IL-18, potentially setting off an inflammatory cascade that leads to cytokine storms [8]. On the other hand, SARS-CoV-2 utilizes Angiotensin Converting Enzyme 2 (ACE2) receptors on host cell surfaces for entry [9,10]. The strong expression of ACE2 receptors and increased release of proprotein convertase contribute to COVID-19-related complications by facilitating viral entry into host cells [10,11]. These characteristics can result in patients developing chronic issues and multi-system complications such as cardiovascular injuries, neuropsychiatric manifestations, myositis, retinopathy, and hearing loss [[12], [13], [14], [15], [16]]. Although initial small-scale studies during the early stages of the pandemic showed promise for Chloroquine (CQ) [[17], [18], [19]], the Food and Drug Administration (FDA) revoked Emergency Use Authorization (EUA) on June 15, 2020, and issued treatment guidelines advising against the use of CQ with or without azithromycin for COVID-19 [[20], [21], [22]].

CQ, a derivative of 4-aminoquinoline, has been extensively utilized for nearly eight decades to prevent and treat malaria. Moreover, CQ is commonly employed to alleviate acute and chronic inflammatory conditions such as rheumatoid arthritis, systemic lupus erythematosus, sarcoidosis, and cancer [[23], [24], [25], [26]].

Our research has revealed that CQ, an antimalarial medication, can effectively combat SARS-CoV-2 infection through various mechanisms. In vitro experiments have demonstrated that low concentrations of CQ can impede COVID-19 infection [27]. Additionally, CQ has shown the capability to obstruct viral entry into cells by increasing the endosomal Potential of Hydrogen (PH) to hinder the endocytic pathway [28], and by interfering with the glycosylation of ACE2 receptors [29], thereby reducing the efficiency of the ACE2-SARS-CoV-2 interaction. Furthermore, CQ possesses immunomodulatory properties that mitigate the inflammatory complications associated with viral diseases by inhibiting the production/release of IL-6 [30], which may synergistically enhance its antiviral effects in vivo.

Despite the established effectiveness of CQ in COVID-19 treatment, patients undergoing this therapy may face increased susceptibility to adverse effects (Fig. 1). Notably, the most severe complications include QTc prolongation and cardiac arrhythmia [31]. Furthermore, common drug-related adverse effects encompass nausea, headache, myopathy, retinopathy, and hearing loss. Therefore, this review offers a comprehensive overview of the latest available data on COVID-19-specific complications encountered by patients treated with CQ, with particular emphasis on the mechanisms underlying CQ-induced complications, and to deliberate on the reasons behind the withdrawal of CQ from first-line treatment options for COVID-19.Fig. 1 The main mechanism of CQ on the complications of the COVID-19. The adverse effects of CQ encompass the following five categories: CQ inhibits various K+ currents and autophagy processes, which may ultimately result in cardiac disorders; Skeletal muscle symptoms are correlated with elevated levels of Creatine Kinase (CK), lysosomal pH, and the chronic activation of Nrf2; CQ induces neuropsychiatric side effects by impeding neuronal calcium currents, promoting dopamine excess, antagonizing prostaglandin E, causing spermidine excess, and disrupting acetylcholine function; The ecological disturbances provoked by CQ can lead to excessive inflammation, potentially leading to gastrointestinal disorders; Additionally, CQ exhibits ototoxic and retinal toxic effects.

Fig. 1

2 Cardiac disorders

COVID-19 can exert a profound influence on the cardiovascular system. Research suggests that certain COVID-19 patients may encounter cardiovascular harm, including endothelial cell damage, cardiac arrhythmias, myocarditis, myocardial interstitial fibrosis, and thrombotic incidents [[32], [33], [34], [35], [36]]. Although not all individuals will manifest these symptoms, healthcare professionals should exercise utmost vigilance regarding COVID-19's possible impact on cardiac wellbeing. Evidence indicates that cardiomyocytes, endothelial cells, and pericytes within the heart possess ACE2 expression, rendering them potential direct targets of SARS-CoV-2 [37].

Initially authorized by the FDA for emergency use in the prophylaxis and/or treatment of COVID-19, CQ medications have been associated with an elevated risk of TdP and QTc prolongation, as well as ventricular arrhythmias in COVID-19 patients. Research indicates that approximately 10 % of COVID-19 patients treated with CQ experience QT prolongation [38]. In comparison to a placebo, one study demonstrated that a dosage of 1000 mg/day of CQ phosphate for three days led to an increase in QTc of 18.4–35 ms by day three. Furthermore, a retrospective analysis conducted in Brazil found that COVID-19 patients treated with CQ exhibited prolonged hospital stays and a higher incidence of QT interval prolongation [39]. Additionally, our investigation revealed clear evidence of ventricular arrhythmias in two out of 28 COVID-19 patients who received high-dose CQ treatment [40].

The cardiovascular adverse effects induced by CQ primarily involve disruptions in K+ currents and the autophagy process of cardiomyocytes. The functionality of K+ channels plays a crucial role in the repolarization of cardiac myocytes. CQ has been shown to hinder various K+ currents, including the inward rectifier K+ (Kir) current (IK1) [41], the rapidly activating delayed rectifier K+ current (IKr) associated with the human Ether-a-go-go-related Gene (hERG) [42,43], the fast transient outward K+ current (Ito) [44], and the ATP-sensitive inward rectifier K+ current (KATP) [45,46]. Intriguingly, inhibiting the cardiac IK1 current has been demonstrated to provoke fatal ventricular arrhythmias [41]. Additionally, the inhibition of hERG current has been linked to QT interval prolongation, potentially precipitating Torsades de Pointes under certain circumstances [47]. These findings suggest that CQ acts as an open channel blocker of the Ito current, potentially inducing proarrhythmic effects in clinical scenarios.

While there is substantial evidence suggesting that autophagy activation may offer benefits in cases of myocardial infarction/reperfusion and ischemic heart disease by safeguarding cardiomyocytes against necroptosis and apoptosis, as well as thwarting myocardial fibrosis and hypertrophy, treatment with CQ could counteract these protective effects by inhibiting autophagic flux [[48], [49], [50], [51], [52], [53], [54], [55], [56]]. CQ has been demonstrated to suppress autophagy, potentially resulting in the inhibition of Ca2+ channels and, consequently, precipitating cardiac disorders such as arrhythmia, cardiac hypertrophy, and heart failure [57]. Moreover, studies have suggested that CQ may induce cardiotoxicity by impeding lysosomal enzymes, including α-galactosidase A, β-galactosidase, and arylsulfatase in cardiomyocytes [58]. Intriguingly, CQ can also influence mitochondrial respiratory chain complexes to elevate levels of ROS and oxidative stress, ultimately instigating heart disease by initiating mitochondrial apoptosis signaling in heart cardiomyocytes [59]. The FDA subsequently revoked the EUA, possibly due to the excessive cardiovascular side effects associated with CQ. Hence, the use of CQ should be cautiously weighed against its anticipated therapeutic benefits and administered under close monitoring.

3 Skeletal muscle disorders

Skeletal muscle symptoms and elevated levels of Creatine Kinase (CK) are frequently observed in individuals affected by COVID-19. Interestingly, studies have established a significant correlation between COVID-19-related skeletal muscle symptoms and signs, and CK levels [60]. CK is released from muscles when there is a disruption of muscle membrane integrity or direct damage to muscular tissue. This often occurs concurrently with an exaggerated inflammatory response, akin to the cytokine release syndrome associated with COVID-19 [60,61].

Recent investigations conducted in China revealed that 44–70 % of hospitalized COVID-19 patients experienced symptoms of myalgia or fatigue, while up to 33 % exhibited elevated CK levels [62,63]. Hence, it is plausible that coronavirus infections can precipitate viral myositis. The occurrence of skeletal muscle injury and myopathy in COVID-19 patients may be linked to increased neutrophil count, decreased lymphocyte count, elevated C-reactive protein levels, and elevated D-dimer levels [60,61]. Rhabdomyolysis is also frequently documented as both an initial presentation and subsequent complication of COVID-19, often associated with elevated inflammatory markers [[64], [65], [66], [67]].

Moreover, the virus may directly infiltrate muscle tissue by binding to the ACE2 receptor expressed on myocytes, leading to the development of myositis [60,68]. Consequently, it has been theorized that COVID-19-induced myopathy could arise as a consequence of the inflammatory cascade [69].

During the initial year of the COVID-19 pandemic, CQ and its derivative Hydroxychloroquine (HCQ) were utilized, but their use has been associated with potential symptoms of myopathy [70]. Administration of CQ may lead to the development of myopathies in individuals, while also affecting CK levels.

A comprehensive narrative review of patients treated with CQ revealed that elevated CK levels were present in 60.7 % of cases, and electromyography data exhibited a myopathic pattern in 54 % of individuals examined [71]. Moreover, muscle biopsies from patients receiving CQ displayed vacuolation in 53.7 % of cases, with curvilinear bodies being the main focus of ultrastructural detection (86.8 %) [71]. The presence of rimmed vacuolar changes in muscle biopsies of patients with antimalarial-induced myopathy is considered the most representative feature observed, as similar pathological features have been confirmed in other neuromuscular disorders such as sporadic and familial inclusion body myositis, oculopharyngeal muscular dystrophy, myofibrillary myopathy, and related myopathies [[72], [73], [74], [75]].

On one hand, CQ is regarded as a weak base due to the presence of a basic side chain, allowing these drugs to accumulate in intracellular compartments, primarily lysosomal organelles. The amphiphilic nature of these compounds contributes to an increase in lysosomal pH, ultimately leading to specific disturbances within the lysosome and subsequent autophagic dysfunctions that result in vacuolar changes in muscle tissue [76]. Additionally, these compounds can specifically inhibit the lysosomal proteinase, cathepsin B, which plays a crucial role in intracellular proteolysis [76]. Importantly, the effects of CQ administration extend beyond peripheral organelles within the cell and appear to involve other signaling pathways as well. One regulatory mechanism involves the transcription factor Nrf2, a critical leucine zipper protein that regulates the expression of antioxidant proteins to mitigate oxidative damage induced by injury and inflammation [77].

In disorders characterized by vacuolar changes affecting muscle function, such as autophagic vacuolar myopathy induced by CQ, chronic activation of Nrf2 can have adverse effects on organ systems. Prolonged activation of Nrf2 in skeletal muscle tissue can lead to alterations in cellular redox balance, thereby contributing to the progression of muscular pathologies [[78], [79], [80]]. In one study, CQ administration was implicated in exacerbating cases of myasthenia gravis [81]. However, despite such findings, there was no significant evidence linking chronic fatigue syndrome with the use of CQ [82]. In conclusion, it is crucial not to overlook the monitoring of skeletal muscles in COVID-19 patients receiving CQ treatment.

4 Neuropsychiatric disorders

COVID-19 is linked to an increased risk of developing psychiatric disorders and the potential exacerbation of pre-existing conditions, as indicated by numerous reports. The spectrum of neuropsychiatric manifestations encompasses symptoms such as hyposmia/anosmia, headache, and neuromuscular dysfunction, extending to seizures, stroke, altered mental status, encephalopathy, and psychiatric disorders, both in the acute and chronic phases. These manifestations underscore their potential to signal deteriorating clinical outcomes and a poor prognosis [[83], [84], [85], [86]].

The utilization of CQ, an antimalarial medication, emerged as an emergency measure for treating COVID-19 in late March and early April 2020, but it is associated with neuropsychiatric side effects such as seizures, coma, and psychosis, particularly in patients with no prior history of psychiatric disorders [87]. A patient who underwent treatment with HCQ for COVID-19 infection was reported to have developed depression accompanied by melancholic features, severe suicidal ideation, and attempted suicide [88]. Several mechanisms have been proposed to explain CQ-induced neuropsychiatric side effects, including the inhibition of neuronal calcium currents [89], dopamine excess [90], prostaglandin E antagonism [91], spermidine excess [92], and acetylcholine dysfunction [93], ultimately resulting in neuropsychiatric symptoms, including suicidal ideation.

Moreover, there is substantial evidence indicating that Central Nervous System (CNS) levels of CQ are significantly higher (ten to thirty times) than serum levels [94], potentially due to interference with P-glycoprotein function in the blood-brain barrier [95]. Additionally, existing research suggests that CQ and HCQ may mildly inhibit the metabolic activity of CYP2D6, which is involved in metabolizing psychiatric medications, while medications affecting CYP2D6 or CYP3A4 could contribute to alterations in the levels of CQ and HCQ [96,97].

Although neuropsychiatric symptoms directly linked to CQ usage are relatively rare, research on this matter remains inconclusive. Therefore, awareness of the potential types of neuropsychiatric complications that may arise in patients receiving CQ treatment, especially those in intensive care units with COVID-19 where prompt clinical decision-making is crucial, could have significant beneficial implications.

5 Gastrointestinal disorders

CQ is believed to be associated with gastrointestinal disorders caused by COVID-19, primarily due to its impact on the gut microbiota. The relative abundance of Bacteroidetes and Firmicutes, as well as the ratio of Bifidobacteria and Lactobacilli, are crucial factors in maintaining gut balance and overall health [98]. Studies have shown that patients receiving HCQ experience a significant decrease in the number of Bacteroidetes, Firmicutes, and Lactobacillus [99]. The expression of ACE2 in the intestinal tract is regulated by intestinal bacteria. Inhibition of intestinal bacteria can lead to downregulation of ACE2 expression, resulting in reduced secretion of AMPs, increased viral survival, and exacerbation of intestinal ecological imbalance [100]. Notably, viral infections can increase the permeability of the gastrointestinal wall to foreign pathogens, allowing invasion of intestinal cells and leading to malabsorption and diarrhea [101]. Moreover, a significant portion (70–80 %) of all immune cells in the human body are located in the gut-associated lymphoid tissue. The gut microbiome plays a crucial role in regulating immune responses and influencing the severity of COVID-19 infection [102]. Some suggest that the interaction and balance between the gut microbiota and the immune system are critical for gut homeostasis. However, dysbiosis caused by CQ may lead to excessive inflammation, resulting in pathological changes in the disease [98]. Therefore, it is essential to pay attention to the regulation of gastrointestinal microbiota in COVID-19 patients after CQ treatment.

6 Other disorders

6.1 Toxity

There is evidence suggesting that COVID-19 infection can trigger a state of diabetogenesis. Similar to other acute infections, severe cases of COVID-19 induce a non-specific activation of the immune system, leading to an excessive release of counter-regulatory hormones and pro-inflammatory cytokines such as IL-6 and TNF-α. These molecules are known to induce insulin resistance and hyperglycemia [103]. As more individuals recognize the potential benefits of the low-cost antiviral and anti-inflammatory capabilities associated with CQ and its derivative HCQ, these drugs have garnered attention in the fight against COVID-19 [104]. Furthermore, HCQ has been found to possess oral hypoglycemic properties that can lower blood sugar levels. Sharing an identical mechanism of action with CQ, HCQ differs in structure only by the presence of an additional hydroxy moiety in one terminal [105]. Thus, CQ holds promise as a potential treatment option for diabetic patients with COVID-19 infection. However, current evidence offers limited support for the effectiveness and safety of CQ and HCQ in treating COVID-19 patients with diabetes. Notably, given their anti-COVID-19 mechanisms of action, the administration of CQ phosphate in patients with severe type 2 diabetes carries the risk of causing harm [106]. Retinopathy incidence represents a severe complication and ranks among the major dose-dependent toxicities associated with CQ usage [107]. Considering the high incidence rate (up to 8 %) of retinopathy resulting from long-term HCQ utilization [108], the American Academy of Ophthalmology has recommended administering CQ at doses <2.3 mg/kg based on the actual body weight of the patient and HCQ at doses <5.0 mg/kg [109]. Therefore, special attention should be paid to the potential ocular side effects of CQ in COVID-19 patients with diabetes mellitus when treating such patients with CQ for COVID-19 infection.

6.2 Ototoxicity

It is widely acknowledged that viral infections can contribute to hearing loss. Recent studies have delved into the potential detrimental effects of the COVID-19 virus on the inner ear, necessitating further investigation. Evidence indicates that viruses can attach to the ACE2 receptor, which is expressed in various organ systems, including the cochlea, cochlear nerve, and CNS. By binding to these receptors, the virus may trigger the immune system, potentially resulting in harmful inflammation and damage to the patient's tissue [[110], [111], [112]].

Differences in lower frequencies may stem from infection spread from the nasopharynx, potentially leading to middle ear involvement. However, presently, there is limited published evidence directly linking COVID-19 to tinnitus. Notably, the use of CQ has been associated with ototoxicity, alongside its established retinal toxicity.

Hearing loss in COVID-19 patients could also result from treatment with CQ and HCQ, included in clinical guidelines for COVID-19 treatment in various countries [60]. While retinal toxicity caused by CQ and HCQ is typically monitored through regular ophthalmological exams, changes in hearing and potential ototoxicity have been overlooked. Some reports have described sensorineural hearing loss, tinnitus, dizziness, and other cochleovestibular symptoms following prolonged therapy with high doses of CQ [113]. Both acute and chronic use of CQ has been linked to cochleovestibular ototoxicity.

CQ preferentially accumulates and binds to melanocytes within the inner ear, leading to various injuries such as damage to sensory hair cells, reduction in neural population, loss of supporting cells, and atrophy of the stria vascularis [114]. Notably, the suggested dosage of CQ for COVID-19 infection significantly surpasses the typical dose for malaria treatment, thereby heightening the risk of ototoxic effects. Individuals experiencing hearing loss, tinnitus, or balance issues should be promptly referred for hearing evaluation and intervention after stabilization.

Further research is essential to assess the potential impact of COVID-19 on hearing health and its interactions with COVID-19 treatments on hearing function. Ototoxic side effects need to be taken into account during therapeutic decision-making to ensure patient safety and prevent or manage hearing loss.

7 Discussion

COVID-19 has already caused significant public health issues around the world, and developing effective pharmacological treatment options is a critical priority in the fight against COVID-19. But after being tested, some prescription drugs—like CQ—were rapidly eliminated from the predetermined treatment regimen. This article combines the various adverse reactions induced by CQ for treating COVID-19 syndrome under the current study and analyzes the research advances on CQ to treat COVID-19 over the past three years. The conclusions that follow can be made in light of the literature review and discussion that has already taken location:1. CQ reduces ACE2 expression in the heart, while also inhibiting cardiac K+ currents and Ca2+ channels, potentially leading to conditions like arrhythmia, cardiac hypertrophy, and heart failure.

2. CQ may induce myopathy and impact CK levels, worsening the symptoms of myasthenia gravis. It can also disrupt lysosomal arrangement and autophagy, potentially exacerbating viral myositis from coronavirus infection.

3. Prolonged CQ treatment for COVID-19 may result in adverse neuropsychiatric effects. It interferes with neurotransmitter function, contributing to neurological and neuropsychiatric symptoms such as epilepsy, coma, and psychosis.

4. CQ usage can disrupt the ecosystem of commensal intestinal microflora, leading to dysbiosis and various gastrointestinal symptoms such as nausea, diarrhea, and vomiting.

5. High doses of CQ administration may induce ocular toxicity, potentially causing retinopathy to develop.

6. In addition to the auditory impacts of the virus, CQ medication may contribute to hearing loss in COVID-19 patients. The risk of ototoxicity could be heightened due to the significantly higher recommended dosage of CQ for treating new coronavirus infections compared to the dose typically prescribed for malaria treatment.

8 Conclusion

Numerous research studies and applications have been conducted to explore the unique therapeutic potential of CQ in treating COVID-19. Despite demonstrating some antiviral and anti-inflammatory properties, its mechanism of action and clinical evidence remain inadequately understood, with notable adverse effects and limitations as depicted in Fig. 1. Particularly, its specific target of action remains unclear, and its relevance is not convincingly established.

The aim of this literature review is to investigate the reasons behind the swift discontinuation of CQ for diagnosing and treating new coronavirus pneumonia. Our focus is on evaluating its acceptability and safety for patients afflicted with the illness, specifically examining both its treatment efficacy and the noteworthy side effects. The significance of this work lies in identifying effective therapeutic medications that can mitigate treatment-related and preventive challenges associated with subsequent inflammatory syndromes akin to COVID-19.

Compared to the extant body of research, this article offers a more comprehensive and systematic discussion that delves into the history of CQ usage against SARS-CoV-2 from multiple perspectives. However, certain deficiencies exist within this study, chiefly: firstly, there is no extensive clinical trial data regarding the use of CQ in managing novel coronavirus syndrome, which precludes sufficient support for the results presented in this article. Secondly, obtaining suitable data can prove tremendously challenging and may engender deviations in the findings. Therefore, it is vital to expand the scope of CQ treatment data available from other viral diseases to ensure the validity of future studies and provide more equitable reference points. Additionally, the literature suggests that researching new diseases using existing, classical therapeutic agents holds great promise for future development, serving as valuable reference material for treatments targeting potential future illnesses. The insights contained within this article demonstrate the immense significance and informative value of mitigating and preventing potential future diseases via CQ administration.

Funding

This work was supported by 10.13039/501100007129 Shandong Provincial Natural Science Foundation (ZR2023QH174 ) and Lin He's Academician Workstation of New Medicine and Clinical Translation at 10.13039/501100008853 Jining Medical University (JYHL2019MS18 ).

Data availability statement

No data was used for the research described in the article.

CRediT authorship contribution statement

Yunlong Jia: Writing – original draft, Resources, Formal analysis, Data curation. Wenjie Tian: Writing – original draft, Visualization, Validation, Supervision. Yuyao Li: Writing – original draft, Visualization, Supervision. Yuyan Teng: Writing – review & editing, Writing – original draft, Supervision. Xiaolin Liu: Writing – original draft, Visualization, Supervision. Zhengyu Li: Writing – review & editing, Writing – original draft, Validation. Mingsheng Zhao: Writing – review & editing, Supervision, Funding acquisition, Conceptualization.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

List of abbreviations

Abbreviation	Definition	
CQ	Chloroquine	
COVID-19	Coronavirus Disease 2019	
SARS-CoV-2	Severe Acute Respiratory Syndrome Coronavirus-2	
IL	Interleukin	
TNF	Tumor Necrosis Factor	
ACE2	Angiotensin Converting Enzyme 2	
PH	Potential of Hydrogen	
FDA	Food and Drug Administration	
EUA	Emergency Use Authorization	
CK	Creatine Kinase	
CNS	Central Nervous System	
HCQ	Hydroxychloroquine	
hERG	human Ether-a-go-go-related Gene	

Acknowledgments

We would like to express our sincere gratitude for the support provided by Shandong Provincial Natural Science Foundation, China and Lin He's Academician Workstation of New Medicine and Clinical Translation at Jining Medical University, China. Their generous support has played a crucial role in enabling this work to be carried out successfully. We are grateful for their commitment to advancing medical research and clinical translation, which has significantly contributed to the progress made in understanding the effects of the COVID-19 virus on multiple organ systems.
==== Refs
References

1 Hao Y.J. Wang Y.L. Wang M.Y. The origins of COVID-19 pandemic: a brief overview Transbound Emerg Dis 69 6 2022 3181 3197 36218169
2 Coronavirus disease (COVID-19) pandemic.[EB/OL]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
3 Wanhella K.J. Fernandez-Patron C. Biomarkers of ageing and frailty may predict COVID-19 severity Ageing Res. Rev. 73 2022 101513
4 Zhang J.J. Dong X. Liu G.H. Risk and protective factors for COVID-19 morbidity, severity, and mortality Clin. Rev. Allergy Immunol. 64 1 2023 90 107 35044620
5 Ahmad Malik J. Ahmed S. Shinde M. The impact of COVID-19 on comorbidities: a review of recent updates for combating it Saudi J. Biol. Sci. 29 5 2022 3586 3599 35165505
6 Tang Y. Liu J. Zhang D. Cytokine storm in COVID-19: the current evidence and treatment strategies Front. Immunol. 11 2020 1708 32754163
7 Lowery S.A. Sariol A. Perlman S. Innate immune and inflammatory responses to SARS-CoV-2: implications for COVID-19 Cell Host Microbe 29 7 2021 1052 1062 34022154
8 Hu B. Huang S. Yin L. The cytokine storm and COVID-19 J. Med. Virol. 93 1 2021 250 256 32592501
9 Verdecchia P. Cavallini C. Spanevello A. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection Eur. J. Intern. Med. 76 2020 14 20 32336612
10 Shang J. Wan Y. Luo C. Cell entry mechanisms of SARS-CoV-2 Proc. Natl. Acad. Sci. U. S. A. 117 21 2020 11727 11734 32376634
11 Alves M. Mahnke L.C. Macedo T.C. The enzymes in COVID-19: a review Biochimie 197 2022 38 48 35090981
12 Louis D.W. Saad M. Vijayakumar S. The cardiovascular manifestations of COVID-19 Cardiol. Clin. 40 3 2022 277 285 35851451
13 Ren A.L. Digby R.J. Needham E.J. Neurological update: COVID-19 J. Neurol. 268 11 2021 4379 4387 33929617
14 Saud A. Naveen R. Aggarwal R. COVID-19 and myositis: what we know so far Curr. Rheumatol. Rep. 23 8 2021 63 34216297
15 Sen M. Honavar S.G. Sharma N. COVID-19 and eye: a review of ophthalmic manifestations of COVID-19 Indian J. Ophthalmol. 69 3 2021 488 509 33595463
16 Kilic O. Kalcioglu M.T. Cag Y. Could sudden sensorineural hearing loss be the sole manifestation of COVID-19? An investigation into SARS-COV-2 in the etiology of sudden sensorineural hearing loss Int. J. Infect. Dis. 97 2020 208 211 32535294
17 Huang M. Tang T. Pang P. Treating COVID-19 with chloroquine J. Mol. Cell Biol. 12 4 2020 322 325 32236562
18 Gautret P. Lagier J.C. Parola P. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Int. J. Antimicrob. Agents 56 1 2020 105949
19 Mccabe G. Sahni D.S. Ramsaha S. Indian J. Community Med. 46 3 2021 380 388 34759472
20 Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine.[EB/OL]. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and.
21 Geleris J. Sun Y. Platt J. Observational study of hydroxychloroquine in hospitalized patients with covid-19 N. Engl. J. Med. 382 25 2020 2411 2418 32379955
22 Borba M.G.S. Val F.F.A. Sampaio V.S. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial JAMA Netw. Open 3 4 2020 e208857
23 Hannon C.W. Mccourt C. Lima H.C. Interventions for cutaneous disease in systemic lupus erythematosus Cochrane Database Syst. Rev. 3 3 2021 Cd007478 33687069
24 Rainsford K.D. Parke A.L. Clifford-Rashotte M. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases Inflammopharmacology 23 5 2015 231 269 26246395
25 Sharma O.P. Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement Arch. Neurol. 55 9 1998 1248 1254 9740120
26 Fong W. To K.K.W. Repurposing chloroquine analogs as an adjuvant cancer therapy Recent Pat. Anti-Cancer Drug Discov. 16 2 2021 204 221
27 Wang M.L. Cao R.Y. Zhang L.K. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Cell Res. 30 3 2020 269 271 32020029
28 Mauthe M. Orhon I. Rocchi C. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion Autophagy 14 8 2018 1435 1455 29940786
29 Wang N. Han S.L. Liu R. Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus Phytomedicine 79 2020 7
30 Savarino A. Boelaert J.R. Cassone A. Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect. Dis. 3 11 2003 722 727 14592603
31 Tonnesmann E. Kandolf R. Lewalter T. Chloroquine cardiomyopathy - a review of the literature Immunopharmacol. Immunotoxicol. 35 3 2013 434 442 23635029
32 Jagia P. Ojha V. Naik N. Myocardial fibrosis detected by cardiovascular magnetic resonance in absence of myocardial oedema in a patient recovered from COVID-19 BMJ Case Rep. 13 12 2020
33 Besler M.S. Arslan H. Acute myocarditis associated with COVID-19 infection AJEM (Am. J. Emerg. Med.) 38 11 2020
34 Wang D.W. Hu B. Hu C. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China JAMA, J. Am. Med. Assoc. 323 11 2020 1061 1069
35 Ratchford S.M. Stickford J.L. Province V.M. Vascular alterations among young adults with SARS-CoV-2 Am. J. Physiol. Heart Circ. Physiol. 320 1 2021 H404 H410 33306450
36 Bryce C Grimes Z Pujadas E Ahuja S Beasley MB Albrecht R Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience Mod Pathol 34 8 2021 1456 1467 10.1038/s41379-021-00793-y 33795830
37 Ragia G. Manolopoulos V.G. Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies Eur. J. Clin. Pharmacol. 76 12 2020 1623 1630 32696234
38 Jankelson L. Karam G. Becker M.L. QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review Heart Rhythm 17 9 2020 1472 1479 32438018
39 Souza-Silva M.V.R. Pereira D.N. Pires M.C. Real-life data on hydroxychloroquine or chloroquine with or without azithromycin in COVID-19 patients: a retrospective analysis in Brazil Arq. Bras. Cardiol. 120 9 2023 e20220935
40 Borba M.G.S. Val F.F.A. Sampaio V.S. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial medRxiv 3 4 2020 208857-e208857
41 Rodríguez-Menchaca A.A. Navarro-Polanco R.A. Ferrer-Villada T. The molecular basis of chloroquine block of the inward rectifier Kir2.1 channel Proc. Natl. Acad. Sci. U. S. A. 105 4 2008 1364 1368 18216262
42 Traebert M. Dumotier B. Meister L. Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells Eur. J. Pharmacol. 484 1 2004 41 48 14729380
43 Vicente J. Zusterzeel R. Johannesen L. Assessment of multi-ion channel block in a phase I randomized study design: results of the CiPA phase I ECG biomarker validation study Clin. Pharmacol. Ther. 105 4 2019 943 953 30447156
44 Wagner M. Riepe K.G. Eberhardt E. Open channel block of the fast transient outward K+ current by primaquine and chloroquine in rat left ventricular cardiomyocytes Eur. J. Pharmacol. 647 1–3 2010 13 20 20807529
45 Noujaim S.F. Stuckey J.A. Ponce-Balbuena D. Structural bases for the different anti-fibrillatory effects of chloroquine and quinidine Cardiovasc. Res. 89 4 2011 862 869 21233253
46 Ponce-Balbuena D. Rodríguez-Menchaca A.A. López-Izquierdo A. Molecular mechanisms of chloroquine inhibition of heterologously expressed Kir6.2/SUR2A channels Mol. Pharmacol. 82 5 2012 803 813 22851715
47 Keating M.T. Sanguinetti M.C. Molecular and cellular mechanisms of cardiac arrhythmias Cell 104 4 2001 569 580 11239413
48 Fu S. Chen L. Wu Y. Gastrodin pretreatment alleviates myocardial ischemia/reperfusion injury through promoting autophagic flux Biochem. Biophys. Res. Commun. 503 4 2018 2421 2428 29969626
49 Liu S. Chen S. Li M. Autophagy activation attenuates angiotensin II-induced cardiac fibrosis Arch. Biochem. Biophys. 590 2016 37 47 26562437
50 Zhang J. Nadtochiy S.M. Urciuoli W.R. The cardioprotective compound cloxyquin uncouples mitochondria and induces autophagy Am. J. Physiol. Heart Circ. Physiol. 310 1 2016 H29 H38 26519034
51 Zuo Z. Zuo P.F. Sheng Z.L. Tetramethylprazine attenuates myocardial ischemia/reperfusion injury through modulation of autophagy Life Sci. 239 2019 117016
52 Qiao S.G. Sun Y. Sun B. Sevoflurane postconditioning protects against myocardial ischemia/reperfusion injury by restoring autophagic flux via an NO-dependent mechanism Acta Pharmacol. Sin. 40 1 2019 35 45 30002490
53 Yan J. Yan J.Y. Wang Y.X. Spermidine-enhanced autophagic flux improves cardiac dysfunction following myocardial infarction by targeting the AMPK/mTOR signalling pathway Br. J. Pharmacol. 176 17 2019 3126 3142 31077347
54 Yu T. Liu D. Gao M. Dexmedetomidine prevents septic myocardial dysfunction in rats via activation of α7nAChR and PI3K/Akt- mediated autophagy Biomed. Pharmacother. 120 2019 109231
55 Guo L. Xu J.M. Mo X.Y. Ischemic postconditioning regulates cardiomyocyte autophagic activity following ischemia/reperfusion injury Mol. Med. Rep. 12 1 2015 1169 1176 25816157
56 Wu X. Zheng D. Qin Y. Nobiletin attenuates adverse cardiac remodeling after acute myocardial infarction in rats via restoring autophagy flux Biochem. Biophys. Res. Commun. 492 2 2017 262 268 28830813
57 Murphy K.R. Baggett B. Cooper L.L. Enhancing autophagy diminishes aberrant Ca(2+) homeostasis and arrhythmogenesis in aging rabbit hearts Front. Physiol. 10 2019 1277 31636573
58 Frustaci A. Morgante E. Antuzzi D. Inhibition of cardiomyocyte lysosomal activity in hydroxychloroquine cardiomyopathy Int. J. Cardiol. 157 1 2012 117 119 22481048
59 Seydi E. Hassani M.K. Naderpour S. Cardiotoxicity of chloroquine and hydroxychloroquine through mitochondrial pathway BMC Pharmacol Toxicol 24 1 2023 26 37085872
60 Romero-Sánchez C.M. Díaz-Maroto I. Fernández-Díaz E. Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOVID registry Neurology 95 8 2020 e1060 e1070 32482845
61 Abenza-Abildúa M.J. Ramírez-Prieto M.T. Moreno-Zabaleta R. Neurological complications in critical patients with COVID-19 Neurologia 35 9 2020 621 627
62 Huang C. Wang Y. Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Lancet 395 10223 2020 497 506 31986264
63 Wang D. Hu B. Hu C. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China JAMA 323 11 2020 1061 1069 32031570
64 Chan K.H. Farouji I. Abu Hanoud A. Weakness and elevated creatinine kinase as the initial presentation of coronavirus disease 2019 (COVID-19) Am. J. Emerg. Med. 38 7 2020 1548.e1 1548.e3
65 Gefen A.M. Palumbo N. Nathan S.K. Pediatric COVID-19-associated rhabdomyolysis: a case report Pediatr. Nephrol. 35 8 2020 1517 1520 32447505
66 Jin M. Tong Q. Rhabdomyolysis as potential late complication associated with COVID-19 Emerg. Infect. Dis. 26 7 2020 1618 1620 32197060
67 Taxbro K. Kahlow H. Wulcan H. Rhabdomyolysis and acute kidney injury in severe COVID-19 infection BMJ Case Rep. 13 9 2020
68 Ferrandi P.J. Alway S.E. Mohamed J.S. The interaction between SARS-CoV-2 and ACE2 may have consequences for skeletal muscle viral susceptibility and myopathies J. Appl. Physiol. 129 4 2020 864 867 1985 32673162
69 Özdağ Acarli A.N. Samanci B. Ekizoğlu E. Coronavirus disease 2019 (COVID-19) from the point of view of neurologists: observation of neurological findings and symptoms during the combat against a pandemic Noro Psikiyatr Ars 57 2 2020 154 159 32550783
70 Gevers S. Kwa M.S.G. Wijnans E. Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19 Clin. Microbiol. Infect. 26 9 2020 1276 1277 32422406
71 Carvalho A. a S. Side effects of chloroquine and hydroxychloroquine on skeletal muscle: a narrative review Curr Pharmacol Rep 6 6 2020 364 372 33163329
72 Eadie M.J. Ferrier T.M. Chloroquine myopathy J. Neurol. Neurosurg. Psychiatry 29 4 1966 331 337 5229994
73 Kwon J.B. Kleiner A. Ishida K. Hydroxychloroquine-induced myopathy J. Clin. Rheumatol. 16 1 2010 28 31 20051753
74 Vinciguerra C. Sicurelli F. Fioravanti A. Hydroxychloroquine neuromyotoxicity: a case with rapid course and complete recovery Neurol. Sci. 36 12 2015 2293 2294 26260758
75 Khosa S. Khanlou N. Khosa G.S. Hydroxychloroquine-induced autophagic vacuolar myopathy with mitochondrial abnormalities Neuropathology 38 6 2018 646 652 30411412
76 Posada C. García-Cruz A. García-Doval I. Chloroquine-induced myopathy Lupus 20 7 2011 773 774 21300683
77 Tebay L.E. Robertson H. Durant S.T. Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease Free Radic. Biol. Med. 88 Pt B 2015 108 146 26122708
78 Khelfi A. Azzouz M. Abtroun R. [Direct mechanism of action in toxic myopathies] Ann. Pharm. Fr. 75 5 2017 323 343 28526123
79 Duleh S. Wang X. Komirenko A. Activation of the Keap1/Nrf2 stress response pathway in autophagic vacuolar myopathies Acta Neuropathol Commun 4 1 2016 115 27799074
80 Bellezza I. Giambanco I. Minelli A. Nrf2-Keap1 signaling in oxidative and reductive stress Biochim. Biophys. Acta Mol. Cell Res. 1865 5 2018 721 733 29499228
81 Aksoy E. Oztutgan T. COVID-19 presentation in association with myasthenia gravis: a case report and review of the literature Case Rep Infect Dis 2020 2020 8845844
82 Simani L. Ramezani M. Darazam I.A. Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19 J. Neurovirol. 27 1 2021 154 159 33528827
83 Iltaf S Sr. Fatima M. Salman S Sr. Frequency of neurological presentations of coronavirus disease in patients presenting to a tertiary care hospital during the 2019 coronavirus disease pandemic Cureus 12 8 2020 9846-e9846
84 Fan S. Xiao M. Han F. Neurological manifestations in critically ill patients with COVID-19: a retrospective study Front. Neurol. 11 2020
85 Xiong W. Mu J. Guo J. New onset neurologic events in people with COVID-19 in 3 regions in China Neurology 95 11 2020 E1479 E1487 32554771
86 Frontera J.A. Sabadia S. Lalchan R. A prospective study of neurologic disorders in hospitalized patients with COVID-19 in New York city Neurology 96 4 2021 E575 E586 33020166
87 Alkadi H.O. Antimalarial drug toxicity: a review Chemotherapy 53 6 2007 385 391 17934257
88 Costanza A. Placenti V. Amerio A. Chloroquine/Hydroxychloroquine use and suicide risk: hypotheses for confluent etiopathogenetic mechanisms? Behav. Sci. 11 11 2021
89 O'shaughnessy T.J. Zim B. Ma W. Acute neuropharmacologic action of chloroquine on cortical neurons in vitro Brain Res. 959 2 2003 280 286 12493616
90 Akhtar S. Mukherjee S. Chloroquine induced mania Int. J. Psychiatr. Med. 23 4 1993 349 356
91 Lindenmayer J.P. Vargas P. Toxic psychosis following use of quinacrine J. Clin. Psychiatry 42 4 1981 162 164 7204361
92 Andrews R.C. The side effects of antimalarial drugs indicates a polyamine involvement in both schizophrenia and depression Med. Hypotheses 18 1 1985 11 18 4069032
93 Davis K.L. Berger P.A. Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis Biol. Psychiatr. 13 1 1978 23 49
94 Telgt D.S. Van Der Ven A.J. Schimmer B. Serious psychiatric symptoms after chloroquine treatment following experimental malaria infection Ann. Pharmacother. 39 3 2005 551 554 15728331
95 Crowe A. Ilett K.F. Karunajeewa H.A. Role of P glycoprotein in absorption of novel antimalarial drugs Antimicrob. Agents Chemother. 50 10 2006 3504 3506 16917012
96 Projean D. Baune B. Farinotti R. In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation Drug Metabol. Dispos. 31 6 2003 748 754
97 Somer M. Kallio J. Pesonen U. Influence of hydroxychloroquine on the bioavailability of oral metoprolol Br. J. Clin. Pharmacol. 49 6 2000 549 554 10848718
98 Shen S. Wong C.H. Bugging inflammation: role of the gut microbiota Clin Transl Immunology 5 4 2016 e72 27195115
99 Angelakis E. Million M. Kankoe S. Abnormal weight gain and gut microbiota modifications are side effects of long-term doxycycline and hydroxychloroquine treatment Antimicrob. Agents Chemother. 58 6 2014 3342 3347 24687497
100 Ozkurt Z. Çınar Tanrıverdi E. COVID-19: gastrointestinal manifestations, liver injury and recommendations World J Clin Cases 10 4 2022 1140 1163 35211548
101 Mahajan R.K. Paul G. Mahajan R. Systemic manifestations of COVID-19 J. Anaesthesiol. Clin. Pharmacol. 36 4 2020 435 442 33840920
102 Yeoh Y.K. Zuo T. Lui G.C. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19 Gut 70 4 2021 698 706 33431578
103 Group R.C. Horby P. Lim W.S. Dexamethasone in hospitalized patients with covid-19 N. Engl. J. Med. 384 8 2021 693 704 32678530
104 Gao J. Tian Z. Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies Biosci Trends 14 1 2020 72 73 32074550
105 Singh A.K. Singh A. Shaikh A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: a systematic search and a narrative review with a special reference to India and other developing countries Diabetes Metabol. Syndr. 14 3 2020 241 246
106 Gao X. Jing X. Wang J. Safety considerations of chloroquine in the treatment of patients with diabetes and COVID-19 Chem. Biol. Interact. 361 2022 109954
107 Jorge A. Ung C. Young L.H. Hydroxychloroquine retinopathy - implications of research advances for rheumatology care Nat. Rev. Rheumatol. 14 12 2018 693 703 30401979
108 Melles R.B. Marmor M.F. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy JAMA Ophthalmol 132 12 2014 1453 1460 25275721
109 Marmor M.F. Kellner U. Lai T.Y. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision) Ophthalmology 123 6 2016 1386 1394 26992838
110 Harenberg J. Jonas J.B. Trecca E.M.C. A liaison between sudden sensorineural hearing loss and SARS-CoV-2 infection Thromb. Haemostasis 120 9 2020 1237 1239 32725610
111 Delgado-Roche L. Mesta F. Oxidative stress as key player in severe acute respiratory syndrome coronavirus (SARS-CoV) infection Arch. Med. Res. 51 5 2020 384 387 32402576
112 Nile S.H. Nile A. Qiu J. COVID-19: pathogenesis, cytokine storm and therapeutic potential of interferons Cytokine Growth Factor Rev. 53 2020 66 70 32418715
113 Scherbel A.L. Harrison J.W. Atdjian M. Further observations on the use of 4-aminoquinoline compounds in patients with rheumatoid arthritis or related diseases Cleve. Clin. Q. 25 2 1958 95 111 13523829
114 Hadi U. Nuwayhid N. Hasbini A.S. Chloroquine ototoxicity: an idiosyncratic phenomenon Otolaryngol. Head Neck Surg. 114 3 1996 491 493 8649890
